- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Indrayani Biotech Limited has announced a board meeting to approve the financial results for the quarter and half-year ended March 31, 2025. The audited consolidated results show a net loss of Rs 610.75 lakhs for the year, compared to a profit of Rs 1,042.25 lakhs in the previous year. Revenue stood at Rs 13,022.84 lakhs, down from Rs 16,622.56 lakhs. Total expenses rose to Rs 13,909.77 lakhs. The consolidated balance sheet reflects total assets of Rs 268.17 Cr and equity of Rs 99.92 Cr, with borrowings at around Rs 134.07 Cr. Cash flow from operations was negative at Rs 6.74 Cr, while investing activities generated Rs 24.74 Cr, and financing activities used Rs 18.30 Cr. The results include figures from multiple subsidiaries, some audited and some certified by management.